BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adnan F, Khan NU, Iqbal A, Ali I, Petruzziello A, Sabatino R, Guzzo A, Loquercio G, Botti G, Khan S, Naeem M, Khan MI. Interleukin-6 polymorphisms in HCC patients chronically infected with HCV. Infect Agent Cancer 2020;15:21. [PMID: 32266003 DOI: 10.1186/s13027-020-00285-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Ihsan M, Khan NU, Ismail M, Hussain M, Munir I. Significant association of candidate genes (AGTR1 and TGF-β1) polymorphism with diabetic nephropathy in diabetes mellitus type 2 patients.. [DOI: 10.21203/rs.3.rs-2303500/v1] [Reference Citation Analysis]
2 Jehanzeb M, Khan NU, Hussain M, Subrina J, Ayub S, Mustafa A. Association of candidate genes (ALR2, RAGE, and VEGF) polymorphisms with diabetic retinopathy in type 2 diabetic patients of Khyber Pakhtunkhwa, Pakistan. Mol Biol Rep 2022. [DOI: 10.1007/s11033-022-08057-x] [Reference Citation Analysis]
3 Badshah Y, Shabbir M, Khan K, Fatima M, Majoka I, Aslam L, Munawar H. Manipulation of Interleukin-6 (IL-6) and Transforming Growth Factor Beta-1(TGFβ-1) towards viral induced liver cancer pathogenesis. PLoS One 2022;17:e0275834. [PMID: 36215278 DOI: 10.1371/journal.pone.0275834] [Reference Citation Analysis]
4 Gong B, Huang L, He Y, Xie W, Yin Y, Shi Y, Xiao J, Zhong L, Zhang Y, Jiang Z, Hao F, Zhou Y, Li H, Jiang L, Yang X, Song X, Kang Y, Tuo L, Huang Y, Shuai P, Liu Y, Zheng F, Yang Z. A genetic variant in IL-6 lowering its expression is protective for critical patients with COVID-19. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-00923-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
5 Srivastava A, Sharma H, Khanna S, Sadhu Balasundaram T, Chowdhury S, Chowdhury R, Mukherjee S. Interleukin-6 Induced Proliferation Is Attenuated by Transforming Growth Factor-β-Induced Signaling in Human Hepatocellular Carcinoma Cells. Front Oncol 2022;11:811941. [DOI: 10.3389/fonc.2021.811941] [Reference Citation Analysis]
6 Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol 2021;11:726213. [PMID: 34900676 DOI: 10.3389/fonc.2021.726213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Omran MM, Mosaad S, Emran TM, Eltaweel FM, Farid K. A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus. J Genet Eng Biotechnol 2021;19:168. [PMID: 34714420 DOI: 10.1186/s43141-021-00262-8] [Reference Citation Analysis]
8 Aleagha OE, Oltulu P, Sadeghi M. Association between interleukin 6 polymorphisms (rs1800796, rs1800795, rs2069837, rs17147230, and rs1800797) and hepatocellular carcinoma susceptibility: a meta-analysis. Clin Exp Hepatol 2020;6:359-66. [PMID: 33511285 DOI: 10.5114/ceh.2020.102171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Si YQ, Wang XQ, Fan G, Wang CY, Zheng YW, Song X, Pan CC, Chu FL, Liu ZF, Lu BR, Lu ZM. Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation. Infect Agent Cancer 2020;15:70. [PMID: 33292429 DOI: 10.1186/s13027-020-00337-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]